NCT00369785
Clinical Trial Information
Trial Number: NCT00369785 (ClinicalTrials.gov)
Disease Type:
- CNS Neoplasm (Primary Tumor) - Miscellaneous
- Miscellaneous Neoplasm - Solid Tumor
Trial Title:
Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain
Study ID:
WFU-91105
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
Title | Description |
---|---|
NCT00369785-D1 | A total of 198 adult brain tumor survivors were randomly assigned to receive donepezil (5 mg for 6 weeks and 10 mg for 18 weeks) or placebo. Neurocognitive tests were assessed at baseline, 12 weeks post randomization, and 24 weeks post randomization. The primary aim of the study was to assess the effect of donepezil on a cognitive composite outcome (consisting of the average of eight standardized tests) at 24 weeks. A secondary aim was to assess the effect of donepezil on the individual tests. There was no significant effect of donepezil on the composite outcome. However, donepezil did significantly improve memory and motor speed/dexterity. This dataset contains all the data used in the publication PMID 25897156. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®